Onrigin Approval Status
FDA Approved: No
Brand name: Onrigin
Generic name: laromustine
Dosage form: Injection
Company: Vion Pharmaceuticals, Inc.
Treatment for: Acute Myeloid Leukemia
Onrigin (laromustine), formerly known as Cloretazine (VNP40101M), is a novel alkylating agent in development for remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML).
Development Status and FDA Approval Process for Onrigin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.